Consultant Jeffrey Casberg says biosimilars are coming on strong and that interchangeability may not be much for the products dispensed through specialty pharmacies because specialty pharmacies are often in frequent touch with physicians.
Melissa Andel, principal of CommonHealth Solutions, discusses Medicare Part D in the future — more particularly in the next year — and why these changes are being made during this year's AMCP Nexus conference.
A panel discussion on prescription digital therapeutics identified them as a sweet spot for value-based agreements and collection of real-world evidence. But should they be paid for through the pharmacy benefit? And is there enough evidence available for payers and PBMs to make sound coverage and formulary decisions? For answers, stay tuned.
The Southern California Medicare Advantage health plan zeroed in on medication adherence among its Black and Latinx members and took a multifaceted approach, which included cultural humility training and pairing staff and members had language and a cultural background in common.